Highbridge Capital Management’s Dare Bioscience DARE Stock Holding History

Highbridge Capital Management’s Portfolio DARE Stock Details DARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-109	Closed	-$37K	–	1544
2015 Q4	$37K	Sell	109 -40	-27%	-$16.6K	﹤0.01%	1445
2015 Q3	$65K	Sell	149 -59	-28%	-$29.7K	﹤0.01%	1452
2015 Q2	$115K	Buy	+208	New	+$143K	﹤0.01%	1332

Other funds holding DARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

PVMCI

Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

Highbridge Capital Management's DARE Position: Q1 2016 in Review

Highbridge Capital Management sold out of Dare Bioscience (DARE) in Q1 2016, closing a stake of 109 shares — an estimated $37K sold.

Highbridge Capital Management first reported a position in DARE in Q2 2015 and held it in 3 quarters. The position peaked at $115K in Q2 2015. 37 funds tracked by Wall St. Rank hold DARE as of Q1 2016.

Highbridge Capital Management reported no remaining Dare Bioscience position as of Q1 2016 after selling out during the quarter.
Highbridge Capital Management sold 109 Dare Bioscience shares in Q1 2016, an estimated $37K.
Highbridge Capital Management first reported a position in Dare Bioscience in Q2 2015 and held it in 3 quarters.
Highbridge Capital Management's Dare Bioscience position peaked at $115K in Q2 2015.
37 funds tracked by Wall St. Rank held Dare Bioscience as of Q1 2016.

Based on Highbridge Capital Management's 13F filing for Q1 2016, filed 16 May 2016.